Everolimus + Everolimus + Paclitaxel
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transitional Cell Carcinoma
Conditions
Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
Trial Timeline
Dec 1, 2010 → Apr 24, 2018
NCT ID
NCT01215136About Everolimus + Everolimus + Paclitaxel
Everolimus + Everolimus + Paclitaxel is a phase 2 stage product being developed by Novartis for Transitional Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01215136. Target conditions include Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01215136 | Phase 2 | Terminated |
Competing Products
20 competing products in Transitional Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine | Astellas Pharma | Phase 1/2 | 41 |
| Pemetrexed + Gemcitabine + Platinol | Eli Lilly | Phase 1/2 | 41 |
| Vepugratinib + EV + Pembrolizumab | Eli Lilly | Phase 3 | 77 |
| durvalumab and tremelimumab | AstraZeneca | Phase 2 | 52 |
| Docetaxel + vandetanib + Placebo | AstraZeneca | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Buparlisib | Novartis | Phase 2 | 52 |
| BEZ235 | Novartis | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Gemcitabine + Cisplatin + Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Nivolumab/Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| vinflunine and best supportive care | Bristol Myers Squibb | Phase 3 | 76 |
| vinflunine | Bristol Myers Squibb | Phase 2 | 51 |
| Dasatinib | Bristol Myers Squibb | Pre-clinical | 22 |
| Docetaxel + Oxaliplatin | Sanofi | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2/3 | 64 |
| Rogaratinib (BAY1163877) + Chemotherapy | Bayer | Phase 2/3 | 62 |
| CG0070 Adenovirus Vector | CG Oncology | Phase 2/3 | 62 |